Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler ...

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its ...

Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten ...

Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more ...

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...

Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.

Myriad Genetics has a 1-year low of $9.76 and a 1-year high of $29.30. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last issued its earnings results on Tuesday, February 25th.

The S&P 500 Index ($SPX) (SPY) today is up +0.79%, the Dow Jones Industrials Index ($DOWI) (DIA) is down -0.02%, and the ...

The latest research report published by Vantage Market Research, titled "An Increase in Demand and Opportunities for the ...

Real-time index price for S&P 500 Index (INX), along with buy or sell indicators, analysis, charts, historical performance, news and more ...